CPRIT Announces $85 Million in Competitive Grant Awards to Support Cancer-Fighting Projects in Texas

CPRIT Announces $85 Million in Competitive Grant Awards to Support Cancer-Fighting Projects in Texas

CPRITEllen Read, 512-305-8483orDavid Gibbs, 512-432-1861

The Cancer Prevention and Research Institute of Texas () today announced more than $85 million in funding to support 75 new scientific research projects and scientific recruits to support a variety of cancer-fighting efforts in Texas. These new awards bring the total tally of funded grants to 502, amounting to nearly $841 million since the Institute opened its doors in 2009.

The 11 new CPRIT awards will potentially bring investigators from institutions such as Harvard, Memorial Sloan-Kettering Cancer Center and Dana-Farber Cancer Institute to the state.

“As we begin our fourth year, we’re taking stock of lessons learned this year and improving our operations to emerge a stronger organization, while continuing our grant approval processes to ensure that worthy projects move forward,” said Bill Gimson, CPRIT executive director. “The projects funded today touch on many aspects of research so that we can tackle cancer on a number of fronts.”

Highlights among the funded projects include:

For a full list of newly funded projects, please visit the grant awards section of CPRIT’s .

Texas voters overwhelmingly approved a constitutional amendment in 2007 establishing CPRIT and authorizing the state to issue $3 billion in bonds to fund groundbreaking cancer research and prevention programs and services in Texas. CPRIT’s goal is to expedite innovation and commercialization in the area of cancer research and to enhance access to evidence-based prevention programs and services throughout the state. CPRIT accepts applications and awards grants for a wide variety of cancer-related research and for the delivery of cancer prevention programs and services by public and private entities located in Texas. More information about CPRIT is available on its website, .

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.